scanX
Dr. Lal Path Labs
add_icon

Dr. Lal Path Labs

2,802.50
-13.50
(-0.48%)
Market Cap
₹23,478.09 Cr
PE Ratio
43.80
Volume
54,047.00
Day High - Low
₹2,830.10 - ₹2,775.00
52W High-Low
₹3,540.00 - ₹2,293.55
hide
Key Fundamentals
Add Ratio
split_icon_default
Market Cap
23,478.09 Cr
EPS
58.48
PB Ratio
9.90
Book Value
285.02
EBITDA
789.00
Dividend Yield
0.85 %
Industry
Healthcare Services
Sector
Healthcare Service Provider
ROE Growth %
-
Debt to Equity
0.10
Analyst Rating and Forecast
- By Refinitiv from23 analysts
BUY
Analysts have suggested that investors can buy this stock
Buy
Buy+69.57 %
+69.57 %
Hold
Hold+4.35 %
+4.35 %
Sell
Sell+26.09 %
+26.09 %
Forecast For
Actual

Company News

View All News
Caret
neutral
Dr. Lal PathLabs amends trust deed for RSU Plan 20252 days ago
Dr. Lal PathLabs Limited executed Fifth Supplementary Trust Deed on December 9, 2025, amending Employee Welfare Trust to incorporate new Restricted Stock Unit Plan 2025 under SEBI regulations.
positive
Dr. Lal PathLabs Increases Authorized Share Capital to INR 200 Crore9 days ago
Dr. Lal PathLabs shareholders approved through postal ballot on December 07, 2025, an increase in authorized share capital from INR 107.96 crore to INR 200 crore, comprising 20 crore equity shares of INR 10 each. The alteration to the Capital Clause of the Memorandum of Association provides the company with enhanced financial flexibility for future growth initiatives.
positive
Dr. Lal PathLabs Launches India's First Comprehensive Complement Testing LaboratoryNov 26, 2025
Dr. Lal PathLabs announced the launch of India's first dedicated Complement Testing Laboratory, offering several tests available in the country for the first time to strengthen autoimmune diagnosis capabilities. The advanced facility brings globally benchmarked complement assays to Indian patients, helping doctors diagnose autoimmune, kidney, and recurrent infection related conditions faster and more accurately at earlier stages.
View more

Peer Comparison Compare Peers on Screener

Competitors
LTP
Market Cap (₹ Cr.)
P/E Ratio
Revenue (₹ Cr.)
YoY Revenue Growth %
Net Profit (₹ Cr.)
YoY Profit Growth %
RSI
Dr. Lal Path Labs
2,802.50
#1 23,478.09
#4 43.80
#1 2,554.80
#8 11.28
#1 492
#5 16.36
27.59
Vijaya Diagnostic Centre
974.35
10,009.00
66.11
699.70
23.06
144
2.85
41.60
Metropolis Healthcare
1,879.90
9,739.28
61.60
1,346.30
10.64
146
13.28
35.37
Thyrocare Technologies
438.70
6,974.60
55.57
702.20
20.80
91
81.06
46.47
Nephrocare Health Services
469.10
4,706.98
70.49
769.90
33.97
67
-
-
Krsnaa Diagnostics
723.00
2,345.32
27.60
742.70
16.70
78
22.45
34.49
Suraksha Diagnostic
276.00
1,437.43
46.94
255.90
15.11
31
-13.73
38.98
One Global Service Provider
675.05
1,319.29
29.43
147.80
#1 134.60
19
#1 760.87
74.41
3B BlackBio DX
1,387.00
1,190.46
#1 24.21
111.60
28.72
48
0.67
59.58
Sastasundar Ventures
301.00
957.50
-105.82
1,170.80
-18.47
-134
90.05
44.59
Growth Rate
Revenue Growth
11.28 %
Net Income Growth
35.88 %
Cash Flow Change
6.27 %
ROE
16.08 %
ROCE
4.10 %
EBITDA Margin (Avg.)
4.50 %

Quarterly Financial Results

Quarterly Financials
Mar 2015
Jun 2015
Sept 2015
Dec 2015
Mar 2016
Jun 2016
Sept 2016
Dec 2016
Mar 2017
Jun 2017
Sept 2017
Dec 2017
Mar 2018
Jun 2018
Sept 2018
Dec 2018
Mar 2019
Jun 2019
Sept 2019
Dec 2019
Mar 2020
Jun 2020
Sept 2020
Dec 2020
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Jun 2025
Sept 2025
Revenue
175
193
221
210
204
229
269
215
227
257
286
270
276
302
328
305
315
350
380
342
314
277
445
466
445
621
513
509
498
511
543
500
505
555
619
557
564
623
682
622
628
698
755
Expenses
128
140
196
119
144
162
182
160
170
184
200
206
203
217
231
227
235
240
257
246
244
218
305
314
309
418
357
388
364
385
390
376
375
395
424
398
401
432
458
443
434
478
507
EBITDA
47
53
25
91
60
67
87
55
57
73
86
64
73
84
98
78
80
110
124
96
69
60
140
152
136
203
156
121
133
126
153
124
130
161
196
159
163
191
224
179
195
220
249
Operating Profit %
25 %
26 %
9 %
37 %
27 %
27 %
31 %
23 %
23 %
26 %
28 %
22 %
24 %
26 %
27 %
22 %
22 %
28 %
30 %
25 %
19 %
18 %
29 %
31 %
28 %
31 %
28 %
22 %
25 %
23 %
27 %
23 %
24 %
27 %
30 %
26 %
27 %
28 %
31 %
26 %
28 %
29 %
31 %
Depreciation
8
7
7
7
7
6
7
7
8
7
8
8
11
9
9
10
10
16
18
19
20
18
20
20
20
19
21
31
38
36
39
38
38
35
36
36
37
35
35
36
36
35
41
Interest
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
4
4
4
4
4
4
4
4
5
5
9
12
9
11
9
9
8
8
7
7
6
6
5
5
5
5
Profit Before Tax
39
47
18
84
53
61
80
47
49
66
78
56
62
75
88
68
69
89
102
73
45
38
117
129
111
179
131
82
84
81
103
77
83
118
152
116
120
150
183
138
153
181
204
Tax
10
16
11
23
18
21
27
16
17
22
27
19
22
26
31
22
22
30
21
19
13
10
30
33
26
46
34
23
21
23
30
23
26
34
42
34
34
42
52
40
-2
47
51
Net Profit
29
31
7
61
35
40
53
31
32
44
51
36
40
50
57
46
47
59
81
55
33
28
87
96
85
134
96
58
62
58
72
54
57
84
111
82
86
108
131
98
156
134
152
EPS in ₹
5.28
5.61
0.99
7.37
4.17
4.88
6.47
3.78
3.80
5.40
6.19
4.39
4.88
6.00
6.92
5.56
5.72
7.14
9.77
6.56
3.94
3.45
10.34
11.44
10.10
15.87
11.49
6.93
7.41
6.97
8.64
6.37
6.84
9.95
13.16
9.77
10.13
12.79
15.52
11.60
18.57
15.88
18.05
Above figures are in Rs. Crores

Balance Sheet

Balance Sheet
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Total Assets
475
625
764
916
1,091
1,374
1,661
2,353
2,386
2,456
2,717
Fixed Assets
150
166
190
208
209
413
447
1,375
1,305
1,228
1,168
Current Assets
282
424
511
623
814
893
1,145
875
973
1,127
1,364
Capital Work in Progress
1
4
18
10
3
11
10
15
5
6
4
Investments
38
64
105
145
185
164
59
66
150
114
327
Other Assets
286
391
452
554
694
786
1,145
898
926
1,109
1,218
Total Liabilities
475
625
764
916
1,091
1,374
1,661
2,353
2,386
2,456
2,717
Current Liabilities
112
91
74
116
138
227
274
500
470
465
402
Non Current Liabilities
20
24
28
8
1
93
111
310
216
105
108
Total Equity
343
510
662
792
951
1,054
1,276
1,544
1,700
1,885
2,207
Reserve & Surplus
260
424
577
734
890
974
1,162
1,425
1,583
1,766
2,089
Share Capital
81
83
83
83
83
83
83
83
83
84
84
Above figures are in Rs. Crores

Cash Flow

Cash Flow
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Net Cash Flow
8
-5
2
37
64
67
48
134
-115
97
-68
Investing Activities
-114
-164
-137
-172
-100
-26
-212
-449
-287
-24
-303
Operating Activities
122
159
171
197
219
284
398
447
456
535
569
Financing Activities
-1
0
-32
13
-55
-190
-139
136
-283
-414
-334
Above figures are in Rs. Crores

Share Holding

% Holding
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Jun 2025
Sept 2025
Promoter
55.23 %
55.23 %
55.23 %
55.23 %
55.23 %
55.05 %
55.05 %
55.05 %
55.03 %
55.01 %
54.61 %
54.60 %
54.60 %
54.60 %
53.92 %
53.91 %
53.91 %
53.79 %
53.21 %
FIIs
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
2.00 %
1.83 %
0.00 %
0.00 %
0.00 %
26.15 %
25.42 %
26.82 %
26.82 %
23.91 %
21.68 %
21.86 %
DIIs
6.47 %
5.61 %
4.84 %
5.58 %
5.69 %
5.30 %
5.09 %
6.19 %
6.55 %
7.33 %
7.97 %
8.61 %
9.69 %
12.71 %
12.89 %
13.17 %
16.08 %
17.91 %
18.49 %
Government
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
Public / Retail
5.70 %
6.24 %
6.93 %
7.45 %
9.03 %
10.44 %
8.24 %
9.03 %
9.50 %
9.31 %
8.37 %
7.26 %
6.47 %
4.91 %
4.10 %
4.01 %
4.11 %
5.23 %
5.19 %
Others
32.60 %
32.92 %
32.99 %
31.74 %
30.05 %
29.22 %
31.63 %
27.73 %
27.09 %
28.35 %
29.05 %
29.53 %
3.09 %
2.35 %
2.27 %
2.10 %
2.00 %
1.38 %
1.25 %
No of Share Holders
68,845
94,123
1,25,953
1,35,068
1,71,846
1,84,508
1,71,602
1,79,636
1,80,163
1,74,444
1,60,679
1,49,901
1,46,741
1,31,189
1,16,606
1,16,236
1,15,699
1,18,656
1,12,703

Dividend History

Annual Cash Flows 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Dividend Per Share (₹) 0.00 3 4.5 6 12 20 12 12 24 24
Dividend Yield (%) 0.00 0.34 0.43 0.43 0.44 0.77 0.67 0.53 0.97 0.85

Corporate Action

Record Date Corporate Action Information Announcement Day LTP at Annoucement LTP at Record Day
19 Dec 2025 BONUS Bonus
1:1
 19 Dec 2025 2,887.55 2,821.75
10 Feb 2021 DIVIDEND Dividend
₹ 6.00 /share
 09 Feb 2021 2,245.95 2,408.65
22 Jul 2021 DIVIDEND Dividend
₹ 8.00 /share
 20 Jul 2021 2,854.95 3,372.15
22 Aug 2021 DIVIDEND Dividend
₹ 6.00 /share
 18 Aug 2021 3,732.50 3,852.65
23 Jun 2022 DIVIDEND Dividend
₹ 6.00 /share
 22 Jun 2022 2,206.55 1,972.85
09 Aug 2022 DIVIDEND Dividend
₹ 6.00 /share
 05 Aug 2022 2,170.30 2,415.45
11 Aug 2023 DIVIDEND Dividend
₹ 6.00 /share
 11 Aug 2023 1,949.85 2,364.35
11 Aug 2023 DIVIDEND Dividend
₹ 6.00 /share
 11 Aug 2023 2,483.50 2,364.35
13 Feb 2024 DIVIDEND Dividend
₹ 12.00 /share
 13 Feb 2024 2,517.40 2,458.75
10 Jun 2024 DIVIDEND Dividend
₹ 6.00 /share
 10 Jun 2024 2,231.55 2,797.75
29 Jun 2024 ANNUAL GENERAL MEETING Annual General Meeting
NA
 29 Jun 2024 2,231.55 2,779.70
20 Aug 2024 DIVIDEND Dividend
₹ 6.00 /share
 20 Aug 2024 3,168.45 3,310.20
23 Oct 2024 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
 23 Oct 2024 3,392.30 3,309.90
05 Nov 2024 DIVIDEND Dividend
₹ 6.00 /share
 05 Nov 2024 3,309.90 3,068.10
30 Jan 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
 30 Jan 2025 2,842.75 2,759.00
05 Feb 2025 DIVIDEND Dividend
₹ 6.00 /share
 05 Feb 2025 2,759.00 2,829.70
06 Feb 2025 EXTRAORDINARY GENERAL MEETING Extraordinary General Meeting
NA
 06 Feb 2025 2,792.50 2,792.50
25 Apr 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
 25 Apr 2025 2,714.10 2,788.20
06 Jun 2025 DIVIDEND Dividend
₹ 6.00 /share
 06 Jun 2025 2,788.20 2,856.80
28 Jun 2025 ANNUAL GENERAL MEETING Annual General Meeting
NA
 28 Jun 2025 2,788.20 2,771.25
31 Jul 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
 31 Jul 2025 3,017.00 3,099.10
06 Aug 2025 DIVIDEND Dividend
₹ 6.00 /share
 06 Aug 2025 3,099.10 3,194.40
31 Oct 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
 31 Oct 2025 3,071.20 3,089.40
07 Nov 2025 DIVIDEND Dividend
₹ 7.00 /share
 07 Nov 2025 3,089.40 3,108.00

Announcements

Amended Trust Deed (ESOP)2 days ago
Intimation Of Record Date For The Purpose Of Issuing Bonus Equity Shares5 days ago
Announcement under Regulation 30 (LODR)-Amendments to Memorandum & Articles of Association9 days ago
Shareholder Meeting / Postal Ballot-Scrutinizer"s Report9 days ago
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseNov 26, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationNov 13, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationNov 08, 2025
Shareholder Meeting / Postal Ballot-Notice of Postal BallotNov 07, 2025
Announcement under Regulation 30 (LODR)-Earnings Call TranscriptNov 06, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationNov 01, 2025
Receipt Of An Assessment Order And Demand Notice Issued By Income Tax DepartmentNov 01, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeOct 31, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseOct 31, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseOct 31, 2025
Announcement under Regulation 30 (LODR)-Investor PresentationOct 31, 2025
Record Date For 2Nd Interim Dividend FY 2025-26Oct 31, 2025
Introduction Of Dr. Lal Pathlabs Employee RSU 2025 (ESOP Scheme)Oct 31, 2025
Announcement under Regulation 30 (LODR)-Dividend UpdatesOct 31, 2025
Corporate Action-Board recommends Bonus IssueOct 31, 2025
Financial Results For The Quarter And Half Year Ended September 30 2025Oct 31, 2025
Board Meeting Outcome for Outcome Of The Board Meeting Held On October 31 2025Oct 31, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationOct 27, 2025
Board Meeting Intimation for Notice Of Board MeetingOct 24, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Oct 07, 2025
Closure of Trading WindowSep 26, 2025
Announcement under Regulation 30 (LODR)-Memorandum of Understanding /AgreementsSep 24, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationAug 26, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 22, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseAug 20, 2025
Announcement under Regulation 30 (LODR)-Earnings Call TranscriptAug 05, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 01, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeJul 31, 2025
Announcement under Regulation 30 (LODR)-Investor PresentationJul 31, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJul 31, 2025
Amendment In Code Of Practices And Procedures For Fair Disclosure Of Unpublished Price Sensitive InformationJul 31, 2025
Record Date For Interim Dividend FY 2025-26Jul 31, 2025
Announcement under Regulation 30 (LODR)-Dividend UpdatesJul 31, 2025
Board Meeting Outcome for Outcome Of Board Meeting - July 31 2025Jul 31, 2025
Results- Financial Results For The Quarter Ended June 30 2025Jul 31, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJul 24, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJul 24, 2025
Board Meeting Intimation for Declaration Of Financial Results For The Quarter Ended June 30 2025 And Interim Dividend If AnyJul 24, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jul 09, 2025
Shareholder Meeting / Postal Ballot-Scrutinizers ReportJun 28, 2025
Shareholder Meeting / Postal Ballot-Outcome of AGMJun 28, 2025
Closure of Trading WindowJun 26, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJun 25, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationJun 05, 2025
Letter Dispatched To The Members Of The Company- Weblink Of The Annual Report FY 2024-25Jun 04, 2025
Business Responsibility and Sustainability Reporting (BRSR)Jun 04, 2025

Mutual Fund Holdings

Funding HouseCurrent Holding %1M Change1M Change %3M Change %Last 6M Trend
Nippon India Multi Cap Fund Direct-Growth
0.25%
151085
0.08%
0.07%
Sundaram Business Cycle Fund Direct - Growth
0.00%
-99875
-1.70%
-1.72%
UTI Multi Cap Fund Direct-Growth
0.85%
-24147
-0.50%
-0.61%
Baroda BNP Paribas Multi Cap Fund Direct-Growth
1.55%
20000
0.14%
0.22%
UTI Healthcare Fund Direct-Growth
0.54%
19566
0.53%
0.54%
Tata Balanced Advantage Fund Direct - Growth
0.97%
11309
0.01%
0.00%
Bajaj Finserv Healthcare Fund Direct-Growth
1.59%
-10337
-1.02%
-1.65%
Baroda BNP Paribas Health and Wellness Fund Direct-Growth
2.50%
10000
0.48%
1.49%
Baroda BNP Paribas Small Cap Fund Direct - Growth
1.98%
10000
0.25%
0.23%
Tata India Pharma & Healthcare Fund Direct-Growth
2.61%
-7770
-0.28%
-0.33%
Motilal Oswal Quant Fund Direct-Growth
0.00%
-5041
-1.08%
-1.12%
Mirae Asset Small Cap Fund Direct-Growth
1.80%
4700
-0.10%
-0.20%
NJ Flexi Cap Fund Direct - Growth
2.56%
4393
-0.06%
0.24%
Samco Multi Asset Allocation Fund Direct-Growth
0.00%
-2414
-0.21%
0.00%
Sundaram Large and Mid Cap Fund Direct-Growth
1.20%
-2307
-0.05%
-0.12%
NJ ELSS Tax Saver Scheme Direct - Growth
3.23%
992
-0.04%
-1.42%
Nippon India Nifty Smallcap 250 Index Fund Direct - Growth
0.58%
976
0.00%
-0.02%
PGIM India Healthcare Fund Direct-Growth
2.86%
-560
-0.04%
0.05%
UTI Quant Fund Direct - Growth
0.40%
540
-0.01%
-0.03%
JioBlackRock Nifty Smallcap 250 Index Fund Direct - Growth
0.58%
472
0.00%
-0.02%
Samco ELSS Tax Saver Fund Direct - Growth
2.38%
412
0.06%
0.21%
DSP Nifty Smallcap250 Quality 50 Index Fund Direct - Growth
2.51%
394
0.01%
-0.06%
Kotak Nifty Smallcap 50 Index Fund Direct - Growth
1.54%
369
-0.02%
-0.09%
ICICI Prudential Nifty Smallcap 250 Index Fund Direct - Growth
0.58%
350
0.00%
-0.01%
HDFC Nifty Smallcap 250 Index Fund Direct-Growth
0.58%
344
0.00%
-0.02%

Technical Indicators

RSI(14)
Neutral
27.59
ATR(14)
Less Volatile
78.27
STOCH(9,6)
Oversold
11.53
STOCH RSI(14)
Oversold
0.00
MACD(12,26)
Bearish
-19.38
ADX(14)
Weak Trend
23.35
UO(9)
Bearish
39.20
ROC(12)
Downtrend And Accelerating
-7.74
WillR(14)
Oversold
-93.35
Bearish
4
Neutral
3
Bullish
2

About Dr. Lal Path Labs

Dr Lal PathLabs is a leading diagnostic healthcare service provider in India. The company operates a nationwide network of medical laboratory centers, offering over 5000 diagnostic tests and related healthcare services. Its infrastructure includes a National Reference Laboratory in New Delhi, Regional Reference Labs in Kolkata, Bangalore, and Mumbai, 371 clinical laboratories, 5,102 patient service centers, and 10,938 pickup points as of March 31, 2023. The company provides services to individual patients, hospitals, healthcare providers, and corporate customers. Its test catalog includes 481 test panels, 2763 pathology tests, and 1947 radiology and cardiology tests. Dr Lal PathLabs has expanded through acquisitions and has several domestic and international subsidiaries. The company continues to grow its network and enhance its technological capabilities to improve its diagnostic services.
Listing Date
23 Dec, 2015(9 Years, 25 days)
Website
https://www.lalpathlabs.com
Chairperson NameArvind Lal
raisewe are part of Raise Financial Services
Heart
built with love

for indians who love to invest & trade

Explore   |   Sitemap
Fundamental Screeners
Technical Screeners
Intraday Screeners
Price & Volume Screeners
Candlestick Screeners
Bullish Stocks Today
Bearish Stocks Today
Stocks Nearing 52W High & Low
Rise & Fall Stocks
Index
Sector
Stock Heatmap
Companies
Sensex Companies
Nifty 50 Companies
Nifty Next 50 Companies
Nifty Bank Companies
Finnifty Companies
Defence Stocks
Semi Conductor Stocks
Renewable Energy Stocks
AI Stocks
Cement Stocks
Penny Stocks
Multibagger Stocks
Breakout Stocks
Dividend Stocks
Large Cap Stocks
Mid Cap Stocks
Small Cap Stocks
About Scanx

We’re building Scanx - to help you express your trading & investing idea, to help you analyse the markets better.

Stock Markets are the true indicator of the growth of any country's economy. We are bullish on India, we are bullish on India's prospects to be one of largest economies of the world. We believe that Stock Markets provide an unique opportunity for all Indians to participate in the growth story of India. We are enabling the same for Indians.
As financial services are becoming more accessible, there is now a large set of Indians today who are financially aware and literate. They value time and seek high quality products & services. Most screening, trading, investing platforms available today are more or less similar to each other, and they have not evolved with time. While both traders & investors have gotten smart about how they make money and build wealth, as users they have continued to use the same products, features, and platforms that were available for years with little or no innovation. We plan to change that - a technology-led platform built for super traders and long term investors.

© 2025 Raise Securities Pvt. Ltd. All rights reserved.

Part of Raise Financial Services

Registered Office: Unit No. 2201, 22nd Floor, Gold Medal Avenue, S.V. Road, Beside Patel Petrol Pump, Piramal Nagar, Goregaon West, Mumbai - 400104